$29.18
3.44% day before yesterday
Nasdaq, Dec 27, 10:19 pm CET
ISIN
US45258D1054
Symbol
IMCR
Sector
Industry

Immunocore Holdings plc - ADR Stock price

$29.18
-3.65 11.12% 1M
-4.60 13.62% 6M
-39.14 57.29% YTD
-40.32 58.01% 1Y
-5.23 15.20% 3Y
+3.18 12.23% 5Y
+3.18 12.23% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.04 3.44%
ISIN
US45258D1054
Symbol
IMCR
Sector
Industry

Key metrics

Market capitalization $1.46b
Enterprise Value $1.04b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 49.60
EV/Sales (TTM) EV/Sales 3.49
P/S ratio (TTM) P/S ratio 4.90
P/B ratio (TTM) P/B ratio 3.89
Revenue growth (TTM) Revenue growth 26.48%
Revenue (TTM) Revenue $297.79m
EBIT (operating result TTM) EBIT $-68.30m
Free Cash Flow (TTM) Free Cash Flow $20.96m
Cash position $901.28m
EPS (TTM) EPS $-0.96
P/E forward negative
P/S forward 4.71
EV/Sales forward 3.35
Short interest 16.37%
Show more

Is Immunocore Holdings plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Immunocore Holdings plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Immunocore Holdings plc - ADR forecast:

13x Buy
76%
3x Hold
18%
1x Sell
6%

Analyst Opinions

17 Analysts have issued a Immunocore Holdings plc - ADR forecast:

Buy
76%
Hold
18%
Sell
6%

Financial data from Immunocore Holdings plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
298 298
26% 26%
100%
- Direct Costs 5.66 5.66
27% 27%
2%
295 295
30% 30%
99%
- Selling and Administrative Expenses 153 153
15% 15%
51%
- Research and Development Expense 208 208
46% 46%
70%
-66 -66
40% 40%
-22%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -68 -68
27% 27%
-23%
Net Profit -47 -47
28% 28%
-16%

In millions USD.

Don't miss a Thing! We will send you all news about Immunocore Holdings plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunocore Holdings plc - ADR Stock News

Neutral
GlobeNewsWire
6 days ago
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
Neutral
GlobeNewsWire
26 days ago
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
Positive
MarketBeat
about 2 months ago
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise.
More Immunocore Holdings plc - ADR News

Company Profile

Immunocore Holdings Plc operates as a holding company. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.

Head office United Kingdom
CEO Bahija Jallal
Employees 497
Founded 2021
Website immunocore.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today